MAIA Company Profile and Key Details

MAIA has shown sold momentum, gaining 40.13% over the past week and 71.88% over the past quarter, though year-to-date performance is up 43.79%. Short-term trend indicators are bearishly aligned (SMA20 -9.11%, SMA50 17.09%, SMA200 17.25%). The stock’s 14-day RSI is 47.95 (neutral), while the ATR of 0.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -40.13% below its high and over 119.54% above its low. Average 10-day trading volume of 1.30 million shares is significantly above the 3-month average of 862.64 thousand, indicating heightened recent market interest.

MAIA Biotechnology, Inc. generated EPS of -$0.74 over the past year. Five-year average earnings growth is -11.4%. The latest quarter delivered EPS of -$0.27. The next quarter is forecast at -$0.13. Next year's EPS is expected at -$6.02. MAIA Biotechnology, Inc. earnings surprise history is a mixed track record. The quarter that ended November 07, 2025, missed forecasts by 42.11%. The prior quarter beat by -25.0%. Over the last six quarters, Apple has recorded several small beats. These include 21.18% in August 13, 2024.

MAIA Biotechnology, Inc. has 32.99 million shares outstanding. The public float is 28.34 million shares, elevated short interest at 2.20% of float. This equals 626.63 thousand shares. The short ratio is 1.43 days. Institutional investors hold 8.81% of the float. Insiders own 21.43%. Vitoc Vlad holds 903.42 thousand shares, Luput Cristian has 437.63 thousand shares and Louie Ngar Yee has 81.70 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

MAIA Biotechnology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.43. This means the shares are trading above this model’s fair value.

MAIA Biotechnology, Inc. (AMEX:MAIA) closed at $1.91 USD, losing -$0.23 (-10.75%) from the previous close of $2.14. The stock is currently mid-range between its 52-week high and low $0.87 and $3.19. With a market capitalization of about $70.73 million, MAIA Biotechnology, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.04). Key stats such as the average daily volume over the past year has been around 884.08 thousand shares, volume is running light vs its 52-week average. Headquartered in Chicago, IL, MAIA Biotechnology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Vlad Vitoc, the company employs approximately 13 people and listed since July 28, 2022. MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer.

MAIA Biotechnology, Inc. trades at a P/E ratio of -2.91, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1557.71 reflecting a rich premium to book value. The P/FCF stands at -4.6, also below market averages. Compared to sector medians, MAIA Biotechnology, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

MAIA Biotechnology, Inc. (AMEX:MAIA) shares are up 43.79% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows MAIA Biotechnology, Inc. trading at a premium to the broader market with a P/E of -2.91. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $14.00, suggesting 632.98% upside. Our AI forecast model points to short-term strength (24.08% over two weeks), a medium-term rise (303.14% over three months), and a longer-term gain (562.3% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that MAIA Biotechnology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 24.08%, with price expected at $2.37 by February 19, 2026, within a range of $2.05 to $2.70 3-Month Outlook: Projected rise of 303.14%, reaching $7.70 by May 05, 2026, with a range of $7.33 to $8.23. 1-Year Outlook: Projected gain of 562.3%, with price at $12.65 by February 05, 2027, within a range of $6.23 to $17.89.